Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.

MLA

Ciccarese, Mariangela, et al. “Dose Intensity and Efficacy of the Combination of Everolimus and Exemestane (EVE/EXE) in a Real-World Population of Hormone Receptor-Positive (ER+/PgR+), HER2-Negative Advanced Breast Cancer (ABC) Patients: A Multicenter Italian Experience.” Breast Cancer Research and Treatment, vol. 163, no. 3, June 2017, pp. 587–94. EBSCOhost, https://doi.org/10.1007/s10549-017-4213-9.

APA

Ciccarese, M., Fabi, A., Moscetti, L., Cazzaniga, M. E., Petrucelli, L., Forcignanò, R., Lupo, L. I., De Matteis, E., Chiuri, V. E., Cairo, G., Febbraro, A., Giordano, G., Giampaglia, M., Bilancia, D., La Verde, N., Maiello, E., Morritti, M., Giotta, F., Lorusso, V., … Surico, G. (2017). Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience. Breast Cancer Research and Treatment, 163(3), 587–594. https://doi.org/10.1007/s10549-017-4213-9

Chicago

Ciccarese, Mariangela, Alessandra Fabi, Luca Moscetti, Maria Elena Cazzaniga, Luciana Petrucelli, Rosachiara Forcignanò, Laura Isabella Lupo, et al. 2017. “Dose Intensity and Efficacy of the Combination of Everolimus and Exemestane (EVE/EXE) in a Real-World Population of Hormone Receptor-Positive (ER+/PgR+), HER2-Negative Advanced Breast Cancer (ABC) Patients: A Multicenter Italian Experience.” Breast Cancer Research and Treatment 163 (3): 587–94. doi:10.1007/s10549-017-4213-9.